543 related articles for article (PubMed ID: 32612604)
1. Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer.
Cifaldi L; Di Santo J; Olive D
Front Immunol; 2020; 11():1132. PubMed ID: 32612604
[No Abstract] [Full Text] [Related]
2. Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy.
Devillier R; Chrétien AS; Pagliardini T; Salem N; Blaise D; Olive D
J Leukoc Biol; 2021 Jun; 109(6):1071-1088. PubMed ID: 32991746
[TBL] [Abstract][Full Text] [Related]
3. Targeting natural killer cells in cancer immunotherapy.
Guillerey C; Huntington ND; Smyth MJ
Nat Immunol; 2016 Aug; 17(9):1025-36. PubMed ID: 27540992
[TBL] [Abstract][Full Text] [Related]
4. Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.
Barrow AD; Colonna M
Semin Immunol; 2017 Jun; 31():30-36. PubMed ID: 28935344
[TBL] [Abstract][Full Text] [Related]
5. Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.
Cifaldi L; Locatelli F; Marasco E; Moretta L; Pistoia V
Trends Mol Med; 2017 Dec; 23(12):1156-1175. PubMed ID: 29133133
[TBL] [Abstract][Full Text] [Related]
6. Editorial: The Natural Killer Cell Interactome in the Tumor Microenvironment: Basic Concepts and Clinical Application.
Anel A; Pardo J; Villalba M
Front Immunol; 2020; 11():872. PubMed ID: 32508819
[No Abstract] [Full Text] [Related]
7. NK cells to cure cancer.
Di Vito C; Mikulak J; Zaghi E; Pesce S; Marcenaro E; Mavilio D
Semin Immunol; 2019 Feb; 41():101272. PubMed ID: 31085114
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of tumor cells escaping from immune surveillance of NK cells.
Ge Z; Wu S; Zhang Z; Ding S
Immunopharmacol Immunotoxicol; 2020 Jun; 42(3):187-198. PubMed ID: 32223464
[TBL] [Abstract][Full Text] [Related]
9. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
Zhang C; Liu Y
Front Immunol; 2020; 11():1295. PubMed ID: 32714324
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.
Cao Y; Wang X; Jin T; Tian Y; Dai C; Widarma C; Song R; Xu F
Signal Transduct Target Ther; 2020 Oct; 5(1):250. PubMed ID: 33122640
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer.
Sivori S; Della Chiesa M; Carlomagno S; Quatrini L; Munari E; Vacca P; Tumino N; Mariotti FR; Mingari MC; Pende D; Moretta L
Front Immunol; 2020; 11():2156. PubMed ID: 33013909
[TBL] [Abstract][Full Text] [Related]
12. Targeting Natural Killer Cells for Tumor Immunotherapy.
Zhang C; Hu Y; Shi C
Front Immunol; 2020; 11():60. PubMed ID: 32140153
[TBL] [Abstract][Full Text] [Related]
13. NK Cell-Based Immune Checkpoint Inhibition.
Khan M; Arooj S; Wang H
Front Immunol; 2020; 11():167. PubMed ID: 32117298
[TBL] [Abstract][Full Text] [Related]
14. Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade.
Bonavita E; Bromley CP; Jonsson G; Pelly VS; Sahoo S; Walwyn-Brown K; Mensurado S; Moeini A; Flanagan E; Bell CR; Chiang SC; Chikkanna-Gowda CP; Rogers N; Silva-Santos B; Jaillon S; Mantovani A; Reis e Sousa C; Guerra N; Davis DM; Zelenay S
Immunity; 2020 Dec; 53(6):1215-1229.e8. PubMed ID: 33220234
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
Carnevalli LS; Ghadially H; Barry ST
Front Immunol; 2021; 12():633685. PubMed ID: 33953710
[TBL] [Abstract][Full Text] [Related]
16. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
Davis ZB; Vallera DA; Miller JS; Felices M
Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
[TBL] [Abstract][Full Text] [Related]
17. Immunosenescence: limitations of natural killer cell-based cancer immunotherapy.
Tarazona R; Sanchez-Correa B; Casas-Avilés I; Campos C; Pera A; Morgado S; López-Sejas N; Hassouneh F; Bergua JM; Arcos MJ; Bañas H; Casado JG; Durán E; Labella F; Solana R
Cancer Immunol Immunother; 2017 Feb; 66(2):233-245. PubMed ID: 27530271
[TBL] [Abstract][Full Text] [Related]
18. NK cell-based immunotherapy for cancer.
Fang F; Xiao W; Tian Z
Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
[TBL] [Abstract][Full Text] [Related]
19. Natural killer cell-mediated immunosurveillance of human cancer.
Malmberg KJ; Carlsten M; Björklund A; Sohlberg E; Bryceson YT; Ljunggren HG
Semin Immunol; 2017 Jun; 31():20-29. PubMed ID: 28888619
[TBL] [Abstract][Full Text] [Related]
20. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
